Pulmonary Arterial Hypertension Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the pulmonary arterial hypertension market size evolved in recent years?
There has been significant growth in the market size for pulmonary arterial hypertension in recent years. The industry, currently valued at $8.47 billion in 2024, is projected to reach a value of $9.24 billion in 2025, expanding at a compound annual growth rate (CAGR) of 9.1%. The upward trend during the preceding years can be linked to an increase in awareness and diagnosis of pulmonary arterial hypertension (PAH), a rise in healthcare spending, aging population growth, the development of more treatment options for pulmonary arterial hypertension, and an increase in research and development activities related to pulmonary hypertension.
What are the predictions for the pulmonary arterial hypertension market size in the coming years?
The market size for pulmonary arterial hypertension is predicted to witness significant expansion in the upcoming years, ballooning to an estimated value of $12.97 billion by 2029, which equates to a compound annual growth rate (CAGR) of 8.8%. This projected development during the forecast time frame is inclined towards the implementation of cutting-edge treatments for pulmonary arterial hypertension, amplification of primordial detection and diagnosis, a growing set of potential PAH drugs and therapies, the incorporation of precision medicine into PAH healing procedures, and the proliferation of healthcare infrastructure in developing markets. Within this forecast timeframe, the market is set to be shaped by progression in medical imaging and diagnostic technologies, cooperative efforts and alliances in drug creation, a shift towards patient-focused strategies in managing pulmonary arterial hypertension and a rising trend in applying combination therapies.
Get your pulmonary arterial hypertension market report here!
What key factors are fueling the growth of the pulmonary arterial hypertension market?
The surge in the instances of pulmonary arterial hypertension (PAH) disease is driving the growth of the PAH market. The mounting occurrence of PAH diseases and corresponding hospitalization of patients for therapy is anticipated to enhance the demand for corresponding drugs in the forecast period. A study by the National Organization for Rare Disorders, Inc. discloses that PAH is projected to affect one to two people per million each year in the USA, thereby translating to 500 to 1000 new cases annually, with similar incidence rates anticipated in Europe.
How is the global pulmonary arterial hypertension market divided into key segments?
The pulmonary arterial hypertension market covered in this report is segmented –
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp
Who are the key firms paving the way for growth in the pulmonary arterial hypertension market?
Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.
Which trends are expected to transform the pulmonary arterial hypertension market?
The pulmonary arterial hypertension market is witnessing innovation from major companies to enhance treatment options and outcomes for patients grappling with this severe ailment. Notably, Merck & Co. Inc., a leading US-based multinational pharmaceutical firm, introduced Winrevair in March 2024. Winrevair holds the distinction of being the first therapy approved by the US-based federal agency, Food and Drug Administration (FDA), that targets activin signaling for pulmonary arterial hypertension (PAH). The uniqueness of this treatment lies in its mechanism, where it reinstates the balance between pro- and anti-proliferative signals, thereby controlling the vascular cell proliferation linked with PAH. It subsequently ushers in a new genre of therapy for this critical condition.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5954
What regions are contributing significantly to the growth of the pulmonary arterial hypertension market?
North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024
Blood Collection Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report
Anticoagulants Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
